Cord Blood Therapy Shows Promise for Cerebral Palsy, Study Finds
A recent meta-analysis published in Pediatrics in April 2025 provides statistical evidence that umbilical cord blood cell therapy can effectively improve gross motor skills in children with cerebral palsy (CP), when combined with rehabilitation. The research, an Individual Participant Data Meta-Analysis (IPDMA), analyzed data from over 400 children with CP across 11 studies.
What is Cerebral Palsy?
Cerebral palsy is a group of disorders affecting a person’s ability to move and maintain balance and posture. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 345 children have been identified with cerebral palsy.
Key Findings of the Meta-Analysis
The IPDMA study revealed that cord blood treatment, in conjunction with rehabilitation, leads to significantly greater improvements in gross motor skills compared to rehabilitation alone. Researchers characterized the clinical effect of cord blood therapy as “a large treatment effect” relative to standard physical therapy interventions for CP.
- At 6 months post-therapy, participants receiving cord blood treatment showed an average improvement of 1.36 points on the Gross Motor Function Measure-66 (GMFM-66) motor skill score, compared to the control group (95% CI: 0.41, 2.32; p=0.005).
- By 12 months, the average improvement in GMFM-66 scores between the cord blood-treated group and controls was 1.42 points (95% CI: 0.31, 2.52; p=0.012).
Responder Subgroups and Dosage
The study also indicated that improvements in motor scores typically peak between 6 and 12 months after cord blood cell therapy. A dose-response trend was observed, suggesting that higher cell doses may correlate with greater improvements in motor skills. Children under five years of age who had some walking ability, either independently or with assistance, before therapy were identified as best responders.
What is Cord Blood and How Does it Work?
Umbilical cord blood contains hematopoietic stem cells, which can differentiate into various cell types. The Parent’s Guide to Cord Blood Foundation explains that these cells have the potential to repair damaged tissues and reduce inflammation, potentially contributing to improved motor function in children with CP.
Looking Ahead
This meta-analysis provides encouraging evidence for the potential of cord blood therapy as a treatment option for cerebral palsy. Further research is needed to optimize treatment protocols, identify ideal candidates, and fully understand the long-term effects of this therapy. The findings underscore the importance of continued investigation into innovative approaches to improve the lives of children with CP.
Frequently Asked Questions
- What is the GMFM-66? The Gross Motor Function Measure-66 (GMFM-66) is a standardized assessment tool used to evaluate gross motor skills in children with cerebral palsy.
- Is cord blood therapy a cure for cerebral palsy? No, cord blood therapy is not a cure for cerebral palsy, but it can significantly improve gross motor function when combined with rehabilitation.
- Where can I find more information about cord blood banking? The Parent’s Guide to Cord Blood Foundation is a valuable resource for information about cord blood banking and potential therapeutic uses.